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Hospitals engaged in medical tourism can turn crisis into opportunity
The global spread of bacteria carrying the New Delhi metallo-β-lactamase-1 (NDM-1) enzyme through India, Pakistan, and the United Kingdom-and now half a dozen other countries-has sparked much media coverage. The outbreak's importance stems from the broad resistance to all antibiotics except tigecycline and colistin seen in bacterial strains carrying the gene for NDM-1 and from the ready transmission across borders.
The original report of NDM-1 cautioned against medical tourism, suggesting the costs of contracting treatment resistant infection outside the UK might well outweigh the savings of lower priced care abroad. The naming of NDM-1 after New Delhi-its purported place of discovery-further vexed Indian government officials worried about potential fallout for the country's burgeoning medical tourism industry. This added drama has distracted attention from what ought to be the main plot of this story.
Modern advances in health care, from organ transplants to cancer chemotherapy, are reliant on effective antibiotics and vulnerable to resistance. Multidrug resistant strains are no longer an isolated phenomenon, nor confined by political borders. To India's credit, the government is preparing a policy on rational use of antibiotics. Healthcare leaders gather on 22 September 2010 for the World Medical Tourism and Global Healthcare Congress in Los Angeles, and these topics ought to be on their agenda.
Restricting medical tourism will not result in effective quarantine. Foreign travel alone resulted in healthy Swedish volunteers becoming colonised with extended spectrum β-lactamase-producing bacteria. Nor are outbreaks of resistant strains limited to hospitals in low income and middle income countries. Meticillin-resistant Staphylococcus aureus (MRSA) was first reported in the UK in the 1960s and has since spread worldwide. Antibiotic use and resistance levels vary widely even among countries in the European Union.
With a dearth of novel antibiotics in the pipeline, the conservation of existing ones is imperative. Infection control and rational antibiotic use are central to such efforts, but it is also susceptible to the failure of collective action. No hospital can remain an island if other community institutions are not doing their part in infection control. The spread of NDM-1 also suggests that globalisation has redefined the bounds of community. To tackle antibiotic resistance, all involved must "think globally, act locally."
Hospitals engaged in medical tourism can make a difference. These institutions seek to deliver the latest in medical advances to patients. In 2007, 750 000
Subscribe Prescriber education, formulary restriction and preauthorisation, and surveillance strategies are among the components that comprise a programme for antimicrobial stewardship. Viewed from a health system's perspective, how can economic incentives be aligned to support infection control at the individual hospital level? Where healthcare infrastructure is limited, how might infection control differ from measures taken in better resourced hospitals? The Ashoka Changemakers competitions bring together communities to collaborate and to reward and encourage end user innovation. In the same crowdsourcing spirit, novel approaches for infection control might be discovered and piloted.
Hospitals engaged in medical tourism can lead by example. These institutions could pledge to a process to improve infection control and to measure performance for accountability. Such efforts in relation to coronary artery bypass graft surgery have led to the voluntary reporting of risk adjusted outcomes in an online report card. Provenance and peer review: Commissioned, not externally peer reviewed.
